Payment overview · 2025
General Payments
$234.44
12 reported records · 9 companies
Healthcare provider profile · identity verified
Robert J Olson, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · MANKATO, MN · NPI 1356320279
Verified facts
What the public records show
CMS Open Payments records show Robert J Olson, MD received $234.44 in general payments during 2025 across 12 reported records.
Supernus Pharmaceuticals, Inc. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Nuplazid, Vraylar, Wakix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuplazid by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wakix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.01 | 25.2% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $33.55 | 14.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.12 | 13.7% | 2 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $30.06 | 12.8% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.37 | 7.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.67 | 7.5% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.37 | 6.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.73 | 6.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.56 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.44 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $59.01 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $33.55 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $30.06 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 125 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 108 | exact normalized | Medicare Part D |
| WAKIX wakix |
2025 | Wakix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
108 | 13 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
125 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lamotrigine | Lamotrigine | 858 | 93 |
| Quetiapine Fumarate | Quetiapine Fumarate | 670 | 52 |
| Trazodone Hcl | Trazodone Hcl | 497 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 482 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 461 | 57 |
| Bupropion Xl | Bupropion Hcl | 371 | 58 |
| Aripiprazole | Aripiprazole | 361 | 31 |
| Gabapentin | Gabapentin | 348 | 51 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 338 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 330 | 44 |
| Divalproex Sodium Er | Divalproex Sodium | 308 | 25 |
| Lorazepam | Lorazepam | 283 | 36 |
| Buspirone Hcl | Buspirone Hcl | 277 | 42 |
| Clonazepam | Clonazepam | 268 | 39 |
| Olanzapine | Olanzapine | 255 | 30 |
| Risperidone | Risperidone | 248 | 19 |
| Sertraline Hcl | Sertraline Hcl | 248 | 33 |
| Memantine Hcl | Memantine Hcl | 241 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 205 | 21 |
| Mirtazapine | Mirtazapine | 188 | 24 |
| Clozapine | Clozapine | 179 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 177 | 19 |
| Topiramate | Topiramate | 176 | 18 |
| Rexulti | Brexpiprazole | 156 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 154 | 24 |
| Alprazolam | Alprazolam | 141 | 27 |
| Metformin Hcl | Metformin Hcl | 130 | 14 |
| Austedo Xr | Deutetrabenazine | 125 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 120 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 117 | 12 |
| Vraylar | Cariprazine Hcl | 108 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 107 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 91 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 19 |
| Clonidine Hcl | Clonidine Hcl | 79 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 79 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 76 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 76 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 19 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 68 | suppressed |
| Diazepam | Diazepam | 66 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 65 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 51 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 51 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 50 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 47 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 46 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 45 | suppressed |
| Paliperidone Er | Paliperidone | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Austedo | Deutetrabenazine | 38 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 38 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Modafinil | Modafinil | 36 | suppressed |
| Spravato | Esketamine Hcl | 36 | suppressed |
| Armodafinil | Armodafinil | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 33 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 32 | suppressed |
| Caplyta | Lumateperone Tosylate | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Depakote Er | Divalproex Sodium | 25 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Risperdal | Risperidone | 23 | suppressed |
| Zaleplon | Zaleplon | 22 | suppressed |
| Sunosi | Solriamfetol Hcl | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Ingrezza | Valbenazine Tosylate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Dayvigo | Lemborexant | 19 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 16 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Risperidone Odt | Risperidone | 14 | suppressed |
| Adlarity | Donepezil Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Clozapine Odt | Clozapine | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Wakix | Pitolisant Hcl | 12 | suppressed |
| Concerta | Methylphenidate Hcl | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.44 · 12 records | Supernus Pharmaceuticals, Inc. | AUSTEDO XR, FANAPT, NEUROSTAR TMS THERAPY SYSTEM, NUPLAZID, Qelbree, SUBLOCADE, VRAYLAR, VYKAT XR, WAKIX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error